Artificial Vitreous Body Formulated from Biomaterials Obtained from Algae A collaborative effort between Korean scientists has resulted in the creation of an artificial vitreous body for treating retinal detachment. This solution is based on a natural carbohydrate derived from algae. Weiterlesen 144
Optic Nerve Damage: A Path to Regeneration Damage to the optic nerve can lead to irreversible blindness. A newly investigated regeneration factor could change that, researchers of the University of Connecticut (UConn) report in the May 2024 issue of Experimental Neurology. This opens up a completely new field of research – in glaucoma or other types of nerve damage. Weiterlesen 170
AMD: Protein FHR-4 no promising therapeutic target? Over the past decade, researchers at the John A. Moran Eye Center’s Sharon Eccles Steele Center for Translational Medicine (SCTM) have clarified the genetics of AMD, refined the clinical understanding of its natural course of progression, and developed potential new treatments. Publishing in the prestigious journal Nature Communications, the SCTM’s latest AMD research points the field away from a liver-produced protein others had identified as a promising therapeutic target. Weiterlesen 138
Scientists discover a worm with enormous and surprisingly sharp-seeing eyes The Mediterranean marine worm Vanadis can be found around the Italian island of Ponza. Its eyesight rivals that of rodents such as mice and rats. Its eyes weigh about 20 times more than the rest of its head. The worms can see UV light and focus on relatively small objects, tracking them as they move. Weiterlesen 335
ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa VG901 is the first and only clinical-stage therapy designed to deliver a functional CNGA1 gene to retinal photoceptor target cells in retinitis pigmentosa patients / VG901, using ViGeneron’s proprietary next-generation technology platform vgAAV, is administered intravitreally (IVT), offering enhanced ease of delivery, broader vector distribution, and mitigating the risk of retinal damage linked with subretinal administration / VG901 granted Orphan Drug Designation by FDA. Weiterlesen 379
Geographic Atrophy: Aviceda Therapeutics Announces Formation of European Clinical Advisory Board The European Clinical Advisory Board (CAB) is made up of internationally recognized thought leaders in retina. The CAB will provide strategic consultation on the company’s clinical development of its lead asset, AVD-104, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Weiterlesen 347
National Eye Institute: Study points to ‘ground zero’ for AMD development Integrative omics approach finds 87 genes where aging, diet, lifestyle and smoking may take toll by affecting epigenome. Weiterlesen 410
Researchers uncover the microbial secrets of dry eye Insights into the ocular microbiome could have implications beyond eye health. Weiterlesen 355
FDA Approval For Clobetasol Propionate Eye Drop for Post-Operative Inflammation And Pain The first new steroid to the ophthalmic sector in more than a decade: Taiwan-based Formosa Pharmaceuticals and AimMax Therapeutics (United States) announced that the U.S. Food and Drug Administration (FDA) has approved clobetasol propionate ophthalmic suspension 0.05% (APP13007), for the treatment of post-operative inflammation and pain following ocular surgery. Weiterlesen 521
AI has perfect detection rate for severe cases of retinopathy of prematurity The technology could expand global treatment before condition can permanently damage vision. Weiterlesen 646